Geode Capital Management
SGMT icon

Geode Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Geode Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.2M Buy
1,444,019
+1,134,497
+367% +$7.71M ﹤0.01% 2477
2026
Q1 		$1.62M Buy
309,522
+13,666
+5% +$76.2K ﹤0.01% 3207
2025
Q4 		$1.75M Buy
295,856
+12,643
+4% +$90.8K ﹤0.01% 3211
2025
Q3 		$1.94M Buy
283,213
+17,889
+7% +$145K ﹤0.01% 3188
2025
Q2 		$2.02M Buy
265,324
+1,600
+0.6% +$6.75K ﹤0.01% 3137
2025
Q1 		$860K Buy
263,724
+8,488
+3% +$35.6K ﹤0.01% 3355
2024
Q4 		$1.15M Buy
255,236
+2,938
+1% +$14.9K ﹤0.01% 3323
2024
Q3 		$699K Buy
252,298
+91,246
+57% +$281K ﹤0.01% 3479
2024
Q2 		$551K Sell
161,052
-238,747
-60% -$1.1M ﹤0.01% 3535
2024
Q1 		$2.17M Buy
399,799
+279,023
+231% +$2M ﹤0.01% 3085
2023
Q4 		$655K Buy
120,776
+10,075
+9% +$47.5K ﹤0.01% 3513
2023
Q3 		$974K Buy
+110,701
New +$1.47M ﹤0.01% 3331

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Geode Capital Management's SGMT Position: Q2 2026 in Review

Geode Capital Management increased its Sagimet Biosciences (SGMT) stake by 367% in Q2 2026, buying an estimated $7.71M and bringing the position to 1,444,019 shares worth $11.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2477.

Geode Capital Management first reported a position in SGMT in Q3 2023 and has held it in 12 quarters since. 119 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Geode Capital Management held 1,444,019 shares of Sagimet Biosciences worth $11.2M as of Q2 2026.
  • Geode Capital Management bought 1,134,497 Sagimet Biosciences shares in Q2 2026, an estimated $7.71M.
  • Sagimet Biosciences made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2477 holding.
  • Geode Capital Management first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 12 quarters since.
  • 119 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.